New hope for Alzheimer's psychosis: 52-Week safety trial launches
NCT ID NCT07459660
First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study looks at the long-term safety of an experimental drug, ML007C-MA, for people with Alzheimer's disease who experience hallucinations and delusions. It is an open-label extension, meaning all participants will receive the drug for up to 52 weeks. The goal is to see if the drug is safe and tolerable over time. About 210 adults who completed a prior related study are eligible to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site
RECRUITINGDoral, Florida, 33122, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33155, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33173, United States
Conditions
Explore the condition pages connected to this study.